基因芯片技术在乙型肝炎病毒耐药和分型检测中的价值  

Clinical value of gene chip technology in the detection of genotyping and drug-resistant mutation of HBV

作　　者：黄文瑶[1] 张水兰[1] 周敏[2] 陈进宇[2] 

机构地区：[1]广东省深圳市第五人民医院中心实验室,518001 [2]广东省深圳市第三人民医院体检科,518020

出　　处：《国际检验医学杂志》2009年第7期677-679,共3页International Journal of Laboratory Medicine

摘　　要：目的通过基因芯片技术快速检测临床血清样本中乙型肝炎病毒的基因亚型和耐药突变情况。方法同时用荧光定量PCR和基因芯片2种方法检测211例临床慢性HBV感染血清样本，并用DNA测序对基因芯片HBV分型和耐药结果进行验证。结果211例样本荧光PCR定量结果均大于或等于5．0×10^2IU／mL，基因芯片检出阳性210例，未检出的1例样本定量值小于1．0×10^3Iu／mL。210例基因芯片检测阳性的样本，基因芯片检测显示耐药突变病例67例，占31．9％；基因亚型2种，其中B型137例，占65．2％，c型69例，占32．9％，B、C混合感染4例，占1．9％。上述210例样本经DNA测序验证，基因亚型和耐药突变类型完全符合。结论基因芯片技术具有准确、灵敏、高通量的特点，适用于临床乙型肝炎病毒基因分型和耐药突变检测。Objective To rapidly detect genotyping and drug-resistant mutation of HBV by means of gene chip technology. Methods Totally 211 serum samples were collected from the patients with chronic hepatitis B. The serum samples were detected by the FQ-PCR and DNA chip technology were adopted to detect the samples, and then the positive samples were further verified by DNA se- quencing. Results FQ-PCR showed that the loads of HBV DNA were equal to or more than 5.0 ×10^2 IU/mL in the 211 samples. Totally 210 samples were gene chip assay positive; 67 cases （31.9%） were detected as mutations in 210 cases. Among these positive samples detected by DNA chip, 137 cases （65.2%） were genotype B,69 cases （32.9%） were genotype C,4 cases （1.9%） were mixed with genotype B and C. DNA sequencing confirmed the above results. Conclusion HBV Genotyping and Drug-resistant Mutations DNA chip technology is characteristic of accuracy, sensitivity and high-flux, and it can be used in HBV genotyping and drug-resistant mutantion detection.

关 键 词：肝炎病毒 乙型 基因型 寡核苷酸序列分析 抗药性 病毒 

分 类 号：R512.62[医药卫生—内科学] R450[医药卫生—临床医学]